BIOPHARMA
By
Can Merck’s $3 Billion Restructuring Drive Sustainable Growth Amidst Patent Challenges?
About MerckMerck & Co., Inc. (MSD outside US & Canada) is a global biopharmaceutical company dedicated to innovating…
Is Bristol Myers Squibb’s $300M Immunology Venture with Bain Capital Set to Pioneer Next-Gen Autoimmune Therapies?
Key Highlights About Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical leader focused on innovative medicines in oncology, immunology,…
How Is GSK’s Robust Q2 2025 Growth Powering Next-Gen Specialty Medicines and Vaccine Innovation?
Key Highlights Specialty Medicines Fuel Strong Market MomentumGSK’s specialty portfolio, notably in Respiratory, Immunology & Inflammation (+10%) and…
Pfizer Secures Exclusive Global Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
Key Highlights A Bold Bet on BispecificsIn a significant expansion of its oncology pipeline, Pfizer has obtained exclusive…
Can AI-Powered Platforms from Certara, Recursion, and Charles River Cut Drug Development Timelines by 50% as FDA Pushes Beyond Animal Testing?
Key Takeaways FDA’s New Roadmap Sparks Industry Transformation The U.S. FDA has outlined a bold strategy to make…
Will Bayer’s Backing of RedHill’s Opaganib Open New Avenues in Precision Oncology?
Key Takeaways Bayer-Supported Trial Expands Opaganib’s Potential RedHill Biopharma’s collaboration with Bayer has taken center stage with the…
